inclusion criteria: * written informed consent obtained from the patient or his/her legally authorized person. * adult patient (\> 18 years). * pcr-confirmed sars-cov-2 based on nasopharyngeal swab (nps), oropharyngeal swab (ops), tracheal aspirate (ta), bronchial aspirate (ba), or bronchoalveolar lavage fluid (balf) within 14 days prior to icu admission or within 72 hours following icu admission. * radiographic imaging consistent with sars-cov-2 infection (e.g. atypical pneumonia, organizing pneumonia, ground glass opacities) or acute respiratory distress syndrome (ards) within 7 days of diagnosis of sars-cov-2 infection. * a negative pregnancy test in women of child-bearing age. * if a woman is of child-bearing age, she must be willing to use an effective method of contraception for 28 days after the final dose of isavuconazole per manufacturer instructions

inclusion criteria: * written informed consent obtained from the patient or his/her legally authorized person. * adult patient (\> 18 years). * pcr-confirmed sars-cov-2 based on nasopharyngeal swab (nps), oropharyngeal swab (ops), tracheal aspirate (ta), bronchial aspirate (ba), or bronchoalveolar lavage fluid (balf) within 14 days prior to icu admission or within 72 hours following icu admission. * radiographic imaging consistent with sars-cov-2 infection (e.g. atypical pneumonia, organizing pneumonia, ground glass opacities) or acute respiratory distress syndrome (ards) within 7 days of diagnosis of sars-cov-2 infection. * a negative pregnancy test in women of child-bearing age. * if a woman is of child-bearing age, she must be willing to use an effective method of contraception for 28 days after the final dose of isavuconazole per manufacturer instructions

inclusion criteria: - written informed consent obtained from the patient or his/her legally authorized person. - adult patient (> 18 years). - pcr-confirmed sars-cov-2 based on nasopharyngeal swab (nps), oropharyngeal swab (ops), tracheal aspirate (ta), bronchial aspirate (ba), or bronchoalveolar lavage fluid (balf) within 14 days prior to icu admission or within 72 hours following icu admission. - radiographic imaging consistent with sars-cov-2 infection (e.g. atypical pneumonia, organizing pneumonia, ground glass opacities) or acute respiratory distress syndrome (ards) within 7 days of diagnosis of sars-cov-2 infection. - a negative pregnancy test in women of child-bearing age. - if a woman is of child-bearing age, she must be willing to use an effective method of contraception for 28 days after the final dose of isavuconazole per manufacturer instructions

inclusion criteria: - written informed consent obtained from the patient or his/her legally authorized person. - adult patient (> 18 years). - pcr-confirmed sars-cov-2 based on nasopharyngeal swab (nps), oropharyngeal swab (ops), tracheal aspirate (ta), bronchial aspirate (ba), or bronchoalveolar lavage fluid (balf) within 14 days prior to icu admission or within 72 hours following icu admission. - radiographic imaging consistent with sars-cov-2 infection (e.g. atypical pneumonia, organizing pneumonia, ground glass opacities) or acute respiratory distress syndrome (ards) within 7 days of diagnosis of sars-cov-2 infection. - a negative pregnancy test in women of child-bearing age. - if a woman is of child-bearing age, she must be willing to use an effective method of contraception for 28 days after the final dose of isavuconazole per manufacturer instructions